Phase II, multicenter, randomized, placebo-controlled, double-blind, parallel-group, search for failure to evaluate the efficacy and safety of BAY 2433334 in patients who have suffered an acute myocardial infarction
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: BAYER AG
- Phase: II
- Execution start: 14/02/2020
- End of execution: 30/10/2021
- IP: